Morphic’s lead program is an oral treatment for inflammatory bowel disease patients, according to a July 8 news release.
The molecule is also being evaluated to treat patients with ulcerative colitis and Crohn’s disease.
The transaction has been approved by the boards of directors of both com
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.